Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection.

Huabing Yang,Yuxin Chen,Dongcheng Jiang,Xiaoli Feng,Ying Xu, Jiayu Wei,Qingcui Zou,Qiaojiang Yang,Jihong Chen,Xiaoling Jiang, Chunling Qin,Zhenzhen Huang, Chongbing Wu, Ying Zhou,Minghua Li, Liusong Yin

Antibody therapeutics（2023）

引用 0|浏览10

暂无评分

摘要

ISH0339 has demonstrated a favorable safety profile and potent anti-SARS-CoV-2 activities against all current variants of concern. Furthermore, prophylactic and therapeutic application of ISH0339 significantly reduced the viral titer in lungs. Investigational New Drug studies to evaluate the safety, tolerability and preliminary efficacy of ISH0339 for both prophylactic and therapeutic purposes against SARS-CoV-2 infection have been filed.

查看译文

关键词

COVID-19,ISH0339,SARS-CoV-2,bispecific,long-protection,neutralizing,omicron,tetravalent

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要